Mark W.  Kroll net worth and biography

Mark Kroll Biography and Net Worth

Director of Haemonetics
Dr. Kroll joined our Board in 2006 and is a member of both the Compensation Committee and the Technology Committee. He currently serves as an Adjunct Full Professor of Biomedical Engineering at the University of Minnesota. From 1995 until his retirement in 2005, Dr. Kroll held a variety of executive leadership positions at St. Judge Medical, Inc., a global medical device company, including as Senior Vice President and Chief Technology Officer for the Cardiac Rhythm Management division and as Vice President of the Tachycardia Business division. Dr. Kroll has more than 25 years’ experience with cardiovascular devices and instrumentation and is the named inventor of more than 350 U.S. patents as well as numerous international patents.

What is Mark W. Kroll's net worth?

The estimated net worth of Mark W. Kroll is at least $853,550.72 as of March 7th, 2023. Dr. Kroll owns 10,142 shares of Haemonetics stock worth more than $853,551 as of March 28th. This net worth approximation does not reflect any other assets that Dr. Kroll may own. Learn More about Mark W. Kroll's net worth.

How do I contact Mark W. Kroll?

The corporate mailing address for Dr. Kroll and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected]. Learn More on Mark W. Kroll's contact information.

Has Mark W. Kroll been buying or selling shares of Haemonetics?

Mark W. Kroll has not been actively trading shares of Haemonetics during the last quarter. Learn More on Mark W. Kroll's trading history.

Who are Haemonetics' active insiders?

Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.

Are insiders buying or selling shares of Haemonetics?

During the last twelve months, insiders at the medical instruments supplier sold shares 4 times. They sold a total of 9,765 shares worth more than $863,630.52. The most recent insider tranaction occured on September, 12th when insider Stewart W Strong sold 228 shares worth more than $20,668.20. Insiders at Haemonetics own 1.8% of the company. Learn More about insider trades at Haemonetics.

Information on this page was last updated on 9/12/2023.

Mark W. Kroll Insider Trading History at Haemonetics

See Full Table

Mark W. Kroll Buying and Selling Activity at Haemonetics

This chart shows Mark W. Kroll's buying and selling at Haemonetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Haemonetics Company Overview

Haemonetics logo
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $84.16
Low: $82.30
High: $84.16

50 Day Range

MA: $77.18
Low: $71.25
High: $84.61

2 Week Range

Now: $84.16
Low: $70.74
High: $95.26

Volume

298,229 shs

Average Volume

457,464 shs

Market Capitalization

$4.27 billion

P/E Ratio

34.21

Dividend Yield

N/A

Beta

0.34